Advertisement Cytori signs LOI with Astrea International - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Cytori signs LOI with Astrea International

Cytori Therapeutics has signed a binding letter of intent to complete a StemSource cell bank sales agreement with Astrea International.

Astrea has committed to purchase one StemSource cell bank for Singapore following receipt of regulatory clearance in Singapore on a pending application on the use of the Celution system for tissue banking. In addition, Astrea has obtained rights from Cytori to commercialize additional StemSource cell banks in Malaysia and Brunei.

The StemSource cell bank is being marketed on Cytori’s behalf to hospitals in Japan, Korea, Taiwan, and Thailand exclusively by Green Hospital Supply. In addition, Cytori is commercializing the StemSource cell bank directly in Europe and the Middle East and additional countries in Asia.

Ivan Puah of Astrea, said: “The StemSource cell bank will allow patients in Singapore to affordably store their own stem and regenerative cells. We believe cell banking will play an integral role in this industry, as patients will be able to store cells from one procedure so that they may receive them in future procedures.”